Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apogee Therapeutics (APGE) Cash from Operations (2022 - 2026)

Apogee Therapeutics (APGE) reported Cash from Operations of 55570000.0 for Q1 2026, down 14.63% year-over-year from 65094405.81 in Q1 2025, and up 11.3% on a QoQ basis from 62650000.0 in Q4 2025.

Apogee Therapeutics (APGE) has 5 years of Cash from Operations data on file, last reported at 55570000.0 in Q1 2026.

  • Quarterly Cash from Operations fell 14.63% year-over-year to 55570000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 234543000.0 (down 24.75% YoY) and the FY2025 annual result came in at 227450000.0, down 32.88% from the prior year.
  • Cash from Operations rose to 55570000.0 in Q1 2026 per APGE's latest filing, from 62650000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 9189000.0 in Q4 2022 and bottomed at 67714000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 37080000.0 (2024), against an average of 38438857.14.
  • The widest annual swing landed in 2023, when Cash from Operations sank 223.8%; it then grew 7.48% in 2025.
  • Tracing APGE's Cash from Operations over 5 years: stood at 9189000.0 in 2022, then slumped by 223.8% to 29754000.0 in 2023, then plunged by 127.58% to 67714000.0 in 2024, then gained by 7.48% to 62650000.0 in 2025, then climbed by 11.3% to 55570000.0 in 2026.
  • Per Business Quant, the three latest APGE Cash from Operations figures stand at 55570000.0 (Q1 2026), 62650000.0 (Q4 2025), and 54294000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 70.50 Mn
10 Apogee Therapeutics 5.53 Bn 4.47 Bn - -55.57 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -55.57 Mn
Mar 31, 2026 -55.57 Mn
Dec 31, 2025 -62.65 Mn
Dec 31, 2025 -62.65 Mn
Sep 30, 2025 -54.29 Mn
Sep 30, 2025 -54.29 Mn
Jun 30, 2025 -62.03 Mn
Jun 30, 2025 -62.03 Mn
Mar 31, 2025 -48.48 Mn
Mar 31, 2025 -48.48 Mn
Dec 31, 2024 -67.71 Mn
Dec 31, 2024 -67.71 Mn
Sep 30, 2024 -42.52 Mn
Sep 30, 2024 -42.52 Mn
Jun 30, 2024 -29.30 Mn
Jun 30, 2024 -29.30 Mn
Mar 31, 2024 -31.64 Mn
Mar 31, 2024 -31.64 Mn
Dec 31, 2023 -29.75 Mn
Dec 31, 2023 -29.75 Mn
Sep 30, 2023 -19.88 Mn
Sep 30, 2023 -19.88 Mn
Jun 30, 2023 -14.57 Mn
Jun 30, 2023 -14.57 Mn
Mar 31, 2023 -10.56 Mn
Mar 31, 2023 -10.56 Mn
Dec 31, 2022 -9.19 Mn
Dec 31, 2022 -9.19 Mn